Treatment of Cushing Disease With Pituitary-Targeting Seliciclib.

ABSTRACT:

Context

Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic hormone (ACTH) production.

Objective

To evaluate seliciclib as an effective pituitary-targeting treatment for patients with Cushing disease (CD).

Methods

Two prospective, open-label, phase 2 trials, conducted at a tertiary referral pituitary center, included adult patients with de novo, persistent, or recurrent CD who received oral seliciclib 400 mg twice daily for 4 consecutive days each week for 4 weeks. The primary endpoint in the proof-of-concept single-center study was normalization of 24-hour urinary free cortisol (UFC; ≤ 50 µg/24 hours) at study end; in the pilot multicenter study, primary endpoint was UFC normalization

SUBMITTER: Liu NA 

PROVIDER: S-EPMC10210614 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature